Clinical Trial Update: Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17 [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating donepezil hydrochloride (Aricept) for cognitive dysfunction in children with Down syndrome aged 11 to 17 was terminated; results have b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Dysfunction
• Down Syndrome

Drugs mentioned

• Aricept (Donepezil)

Snippet

Sponsor: Eisai Inc. | Conditions: Down Syndrome, Cognitive Dysfunction | Phase 3 | Status: TERMINATED | Results posted: 2018-04-23